Design: Prospective registry cohort with Cox proportional hazards modelling and sensitivity analyses
Population: 227 patients with systemic sclerosis, median follow-up 38 months
Primary outcome: Composite of revised CRISS step 1 complications or all-cause mortality
Effect: 45 events (19.7%); baseline active disease HR 2.21 (95% CI 1.06-4.59); forced vital capacity HR 0.98 per percentage point (0.96-0.99)

Two hundred and twenty-seven patients from a prospective systemic sclerosis registry were scored at baseline on the modified disease activity index, with active disease defined as 2.5 or above, and followed for a median of 38 months. The outcome was a composite of clinically meaningful complications based on revised CRISS step 1 events - interstitial lung disease progression, precapillary pulmonary hypertension, scleroderma renal crisis, heart failure, severe digital ischaemia or severe gastrointestinal dysfunction - or death from any cause.

Forty-two patients (18.5%) had active disease at baseline. Forty-five (19.7%) reached the outcome. Active disease separated the survival curves clearly (log-rank P < 0.001), and in multivariable analysis two variables independently predicted events: baseline active disease (HR 2.21, 95% CI 1.06-4.59) and lower forced vital capacity (HR 0.98 per percentage point, 95% CI 0.96-0.99). Sensitivity analyses using alternative endpoint definitions gave consistent results.

The appeal is the simplicity. Risk stratification in systemic sclerosis has been dominated by interstitial lung disease, and this pairs a bedside composite score with a number already measured at every lung function visit to predict a broader range of organ events - renal crisis, digital ischaemia, gut failure - that fall outside the lung pathway entirely. Neither variable requires anything new to be ordered. Both are usually already in the notes and neither is usually used this way.

Score disease activity at baseline and record the value, rather than assessing activity impressionistically
Use forced vital capacity as a general risk marker, not only as a lung disease measure
An active score should prompt closer surveillance across organs, not only more frequent lung imaging
227 patients from one registry - the hazard ratio is a signal, not a calibrated risk estimate
The composite includes renal crisis and gut failure; stratification should follow those too

Why it matters

It extends risk stratification in scleroderma past interstitial lung disease, using measurements already in the notes.

The statistics, in plain English

The hazard ratio of 2.21 for active disease has a confidence interval from 1.06 to 4.59, whose lower bound sits just above 1. That means the direction is established and the magnitude is not - the data are compatible with a barely detectable effect or a more than fourfold one. The forced vital capacity hazard ratio of 0.98 per percentage point looks trivially close to 1 and is not, because it compounds: a patient 20 percentage points lower carries that 2% increment twenty times over. With 45 events in 227 patients, the multivariable model can support only a small number of variables before it starts fitting noise.